Maximum Dose of Mycophenolate Mofetil
The maximum recommended dose of mycophenolate mofetil (CellCept) for adults is 1.5 g twice daily (3 g/day total), which is FDA-approved for cardiac and hepatic transplant patients, though 1 g twice daily (2 g/day total) is the standard maximum for renal transplant patients and most other indications including lupus nephritis. 1
FDA-Approved Maximum Dosing by Indication
The FDA label clearly delineates maximum doses by transplant type 1:
Renal transplantation: 1 g twice daily (2 g/day total) is the recommended maximum. While 1.5 g twice daily (3 g/day) was studied and shown to be safe, no efficacy advantage was demonstrated, and patients on 2 g/day had a better overall safety profile 1
Cardiac transplantation: 1.5 g twice daily (3 g/day total) is the approved dose 1
Hepatic transplantation: 1.5 g twice daily oral or 1 g twice daily IV (3 g/day or 2 g/day respectively) 1
Dosing in Lupus Nephritis (Off-Label)
For lupus nephritis, the most recent EULAR 2025 guidelines recommend mycophenolate mofetil 1-1.5 g twice daily (or mycophenolate sodium 720-1080 mg twice daily) 2. The KDIGO 2024 guidelines specify maintenance dosing at approximately 750-1000 mg twice daily for mycophenolate mofetil 3. These doses align with the 2-3 g/day total range, staying within or below the FDA maximum.
Dose Adjustments in Renal Impairment
No routine dose adjustment is recommended for patients with renal impairment, even in severe cases (GFR <25 mL/min/1.73 m²). 1 This is a critical clinical point that differs from many other medications:
MPA (the active metabolite) exposure increases by approximately 75% in severe renal impairment, but this is considered clinically manageable 1
MPAG (inactive metabolite) accumulates 3-6 fold in severe renal impairment, but long-term safety data at these levels are lacking 1
In patients with delayed graft function post-transplant, MPA exposure remains comparable to those without delayed function, though MPAG levels are 2-3 fold higher 1
Hemodialysis does not remove MPA or MPAG effectively, so no dose adjustment is needed for dialysis patients 1
Important Caveat for Renal Impairment
While the FDA label states no dose adjustment is necessary, the label also notes that "no data are available on the safety of long-term exposure" to elevated MPAG levels 1. Real-world data from liver transplant patients suggests that those on hemodialysis may benefit from reduced doses around 1000 mg/day to maintain therapeutic MPA levels while avoiding excessive accumulation 4. Monitor MPA trough levels if available, particularly in patients with creatinine >1.4 mg/dL.
Hepatic Impairment
No dose adjustment is recommended for patients with severe hepatic parenchymal disease based on alcoholic cirrhosis studies 1. However, the FDA label acknowledges uncertainty about other etiologies of liver disease. In stable liver transplant recipients, standard dosing appears appropriate 4.
Pediatric Dosing (3 months to 18 years)
For children, dosing is weight-based at 600 mg/m² twice daily, up to a maximum of 1 g twice daily 1. This ensures appropriate exposure while avoiding excessive dosing in smaller patients:
- Body surface area 1.25-1.5 m²: 750 mg twice daily
- Body surface area >1.5 m²: 1 g twice daily (adult dose)
Key Clinical Pitfalls
Do not exceed 3 g/day in any adult patient - higher doses provide no additional efficacy and increase toxicity risk 1
Avoid the combination of norfloxacin plus metronidazole - this reduces MPA exposure by 33% 1. Either antibiotic alone is acceptable.
Avoid rifampin co-administration - causes 67% reduction in MPA exposure 1
Ciprofloxacin and amoxicillin-clavulanate reduce MPA trough levels by ~50% during the first 3-14 days of therapy through disruption of enterohepatic recirculation 1. Consider monitoring if rejection risk is high.
Probenecid increases MPAG exposure 3-fold and MPA 2-fold - use caution with other drugs undergoing renal tubular secretion 1
In patients with hypoalbuminemia, severe renal impairment, or liver disease, total MPA concentrations may be misleadingly low due to altered protein binding, while free (active) MPA may be adequate 5. Free drug measurement may be valuable in these situations.
Concomitant Immunosuppression Effects
Ciclosporin co-therapy reduces MPA exposure by 30-40% compared to tacrolimus or sirolimus by inhibiting enterohepatic recirculation 5. Despite this, the same doses are recommended, though therapeutic drug monitoring may be particularly useful in this setting 6.